Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Osocimab

Copy Product Info
😃Good
Catalog No. T77124Cas No. 2056878-75-0
Alias BAY 1213790

Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases

Osocimab

Osocimab

Copy Product Info
😃Good
Catalog No. T77124Alias BAY 1213790Cas No. 2056878-75-0
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$163In StockIn Stock
5 mg$496In StockIn Stock
10 mg$795-In Stock
25 mg$1,180-In Stock
50 mg$1,580-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases
Targets&IC50
FIX activation:16 nM, Substrate cleavage (FXIa mediated):1.2 nM
In vitro
In human plasma, Osocimab (1.4 nM-1 μM; 30 min) demonstrated inhibition of thrombin production, as well as FXIa-mediated FIX activation (or FIX conversion) with an IC50 of 16 nM and FXIa-mediated substrate cleavage with an IC50 of 1.2 nM [1]. Osocimab, at a concentration of 22.05 mg/mL, inhibited activation of the intrinsic pathway-mediated coagulation cascade [1].
SynonymsBAY 1213790
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetF11/Factor XI
Chemical Properties
Molecular Weight144.46 kDa
Cas No.2056878-75-0
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Osocimab | purchase Osocimab | Osocimab cost | order Osocimab | Osocimab in vitro | Osocimab molecular weight